JAK2 is the most intensively investigated member of the JAK family as it is has been shown to play a major role in tumour growth and progression, plus the pathogenic JAK2V617F mutation is present in the majority of patients with myeloproliferative neoplasms (MPNs) [138,139]. Here, JAK2 is linked to myeloproliferative neoplasm.